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Spontaneous T cell responses against tumors occur
frequently and have prognostic value in patients.
The mechanism of innate immune sensing of immu-
nogenic tumors leading to adaptive T cell responses
remains undefined, although type I interferons (IFNs)
are implicated in this process. We found that sponta-
neous CD8+ T cell priming against tumors was defec-
tive in mice lacking stimulator of interferon genes
complex (STING), but not other innate signaling path-
ways, suggesting involvement of a cytosolic DNA
sensing pathway. In vitro, IFN-b production and den-
dritic cell activation were triggered by tumor-cell-
derived DNA, via cyclic-GMP-AMP synthase (cGAS),
STING, and interferon regulatory factor 3 (IRF3). In
the tumor microenvironment in vivo, tumor cell DNA
was detected within host antigen-presenting cells,
which correlated with STING pathway activation and
IFN-b production. Our results demonstrate that a
major mechanism for innate immune sensing of can-
cer occurs via the host STING pathway, with major
implications for cancer immunotherapy.
INTRODUCTION
Spontaneous T cell responses against human cancers are
believed to contribute to the control of tumor growth, based on
the observed prognostic benefit of an immune infiltrate in the
tumor microenvironment in patients. In metastatic disease, a
preexisting T cell-inflamed tumor microenvironment appears to
be associated with clinical responses to therapeutic vaccines
and other immunotherapies and is being explored as a predictive
biomarker (Gajewski et al., 2010; Hamid et al., 2011; Harlin et al.,
2009). Preliminary data exploring clinical responses to anticyto-
toxic T-lymphocyte-associated protein 4 (CTLA-4) or antiprog-
rammed cell death protein 1 (PD-1) mAbs also have suggested
that patients with clinical benefit have a preexisting CD8+ T cell
infiltrate and associated gene signature (Ji et al., 2012; Spranger
et al., 2013; Topalian et al., 2012). In early-stage colon cancer,830 Immunity 41, 830–842, November 20, 2014 ª2014 Elsevier Inc.the presence of effector-memory CD8+ T cells has powerful
prognostic importance, having been reported to bemore predic-
tive of outcome than tumor-node-metastasis (TNM) stage (Pa-
ge`s et al., 2009). Similar positive prognostic import has been
observed in breast cancer (Mahmoud et al., 2011) and in ovarian
cancer (Hwang et al., 2012). However, the mechanism by which
the host immune system initiates innate immune sensing of
tumors and thereby bridges to induction of an adaptive tumor-
specific T cell response is largely unknown. It has been sug-
gested that endogenous adjuvants released from dying cells
are capable of initiating innate immune cell activation (Jounai
et al., 2012; Kono and Rock, 2008; Marichal et al., 2011; McKee
et al., 2013). In chemotherapy and radiotherapy models, treated
cancer cells were shown to release ATP or/and high-mobility
group protein B1 (HMGB1) and activate dendritic cells (DCs)
via the inflammasome or Toll-like receptor 4 (TLR4) pathways,
respectively, which in turn contributed to activation of antitumor
T cells (Apetoh et al., 2007; Ghiringhelli et al., 2009). These data
have indicated that tumor cell-derived factors can facilitate in-
duction of antitumor immunity that contributes to tumor control
with conventional cancer therapeutics. However, in the context
of a spontaneous natural antitumor T cell response, the factors
and mechanisms necessary to induce innate immune sensing
might be distinct and have not been defined. This represents a
critical knowledge gap, because strategies to trigger this innate
immune activation and generate an endogenous T cell response
might be necessary to expand the fraction of patients who can
derive clinical benefit from current immunotherapies.
Spontaneous tumor antigen-specific T cell priming, when it
does occur, appears to be dependent on host type I IFN produc-
tion and signaling on host cells, via a mechanism that involves
promotion of cross-presentation by CD8a+ DCs (Diamond
et al., 2011; Fuertes et al., 2011). In the current report, we inves-
tigated upstream pathways that might trigger this type I IFN
production in response to tumors. In vivo, we found no evidence
for a major role for host myeloid differentiation primary response
gene 88 (MyD88), Toll/interleukin-1 (IL-1) receptor (TIR) domain-
containing adaptor (TRIF), Toll-like receptor 4 (TLR4), Toll-like
receptor 9 (TLR9), P2X purinoreceptor (P2X7R), or mitochondrial
antiviral-signaling protein (MAVS) for spontaneous priming of
antitumor CD8+ T cells. In contrast, spontaneous CD8+ T cell
priming was severely blunted in Tmem173/ (STING-deficient)
Figure 1. STING and IRF3 Are Required for CD8+ T Cell Priming In Vivo
(A) CFSE-labeled 2C T cell were transferred into WT (n = 6) orMyd88/ (n = 6) mice and B16.SIY melanoma cells were inoculated 1 day later. After 6 days, mice
were sacrificed and splenocytes were stained with anti-CD8 and the clonotypic mAb 1B2 and analyzed by flow cytometry for CFSE dilution.
(B) Trif/ (n = 5), (C) Tlr4/ (n = 4), (D) Tlr9/ (n = 5), (E) P2x7r/ (n = 5), (F) Mavs/ (n = 5), (G) Tmem173/ (STING-deficient) (n = 5), or (H) Irf3/ (IRF3-
deficient) (n = 5) mice were inoculated with 106 B16.SIY melanoma cells. After 7 days, splenocytes were analyzed for SIY-specific IFN-g-producing CD8+ T cell
frequencies by ELISPOT assay.
(I andJ)SIYpeptide-specificpentamer stainingwasperformed inTmem173/ (n= 5) and Irf3/ (n= 5)mice, respectively.WTmicewereusedascontrols. *p<0.05,
**p < 0.01, ***p < 0.001 (Student’s t test). Data representmean ± SEMand are representative of two to three independent experiments. See also Figures S1 and S2.
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tumors was also ablated. In vitro, the only tumor-derived sub-
stance that could induce interferon-b (IFN-b) production was
DNA, which was mediated through cGAS, STING, and IRF3. At
a single cell level, we observed transfer of tumor-derived DNA
into host APCs in vivo, which was associated with TANK-binding
kinase 1 (TBK1) and IRF3phosphorylation, and IFN-bproduction.
Our results demonstrate that a major mechanism for innate im-
mune sensing of cancer is via a cytosolic DNA-STING pathway.
These results open up new opportunities for understanding the
mechanisms explaining a natural immune response in cancer
patients, as well as for developing new therapeutic strategies
through facilitating this innate immune response.
RESULTS
STING and IRF3 Are Required for Spontaneous T Cell
Activation against Tumors In Vivo
Recent work has indicated that host type I IFN production serves
as a bridge between tumor sensing and a spontaneous adaptive
T cell response, via a mechanism involving CD8a+ dendritic cells
(Diamond et al., 2011; Fuertes et al., 2011). We therefore pursued
a working model in which innate immune sensing pathways
might detect tumor-derived factors, induce type I IFN production,
and lead to cross-priming of tumor antigen-specific CD8+ T cells
(Diamond et al., 2011; Fuertes et al., 2011). To begin to address
this question, we utilized gene-targeted mice deficient in specific
innate pathways. To determine whether host TLR pathways wereIrequired for spontaneous CD8+ T cell priming, we utilized
Myd88/ or Trif/ mice. Because MyD88 can function in a
T cell-intrinsic fashion (Zhou et al., 2009), we performed adoptive
transfer of wild-type (WT) CFSE-labeled 2C TCR Tg T cells (that
are specific for the model antigen SIY) into WT or Myd88/
mice and challenged with B16.SIY tumors (Blank et al., 2004).
No defect in T cell proliferation or accumulation of divided cells
was observed in Myd88/ hosts (Figure 1A). For interrogation
of the other innate immune pathways, we implanted B16. SIY
melanoma cells and measured endogenous immune response
using IFN-g ELISPOT and SIY peptide/Kb pentamer flow cytom-
etry. Endogenous CD8+ T cell priming against tumor-derived SIY
was intact in Trif/ mice (Figure 1B), suggesting that the TLR
system (Ishii et al., 2006; Stetson and Medzhitov, 2006) is not
mandatory. We also examined CD8+ T cell responses in mice
lacking TLR4 or TLR9, and no defect was observed using either
IFN-g ELISPOT (Figures 1C and 1D) or SIY peptide/Kb pentamer
staining (see Figures S1A and S1B available online). A second
candidate mechanism of innate immune sensing is through
extracellular ATP, as it has been suggested that dying tumor cells
might release ATP, which could be sensed by P2X7R on antigen-
presenting cells (APCs) (Ghiringhelli et al., 2009). However, we
found no defect in spontaneous priming of CD8+ T cells against
tumor-associated antigens in P2x7r/ mice (Figure 1E). We
also examined a role for the defined RNA sensing pathway
using Mavs/ mice, which lack the critical adaptor molecule
for retinoic acid-inducible gene I (RIG-I) and melanoma differen-
tiation-associated protein 5 (MDA5)-dependent innate immunemmunity 41, 830–842, November 20, 2014 ª2014 Elsevier Inc. 831
Figure 2. Tmem173–/– Mice and Irf3–/– Mice Show Defective Tumor Control
(A and B) 1969 tumor cells were inoculated into WT, Tmem173/, or Irf3/ mice and tumor growth was recorded on the indicated days.
(C) WT or Tmem173/ mice (129 background) were inoculated with 106 B16.SIY melanoma cells and tumor size was measured over time.
(D–F) B16.SIY tumor cells (106 cells per mouse) were injected into the indicated mice subcutaneously, and tumor growth was measured on the indicated days.
*p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test). Data represent mean ± SEM and representative of at least two independent experiments.
Immunity
Innate Immune Sensing of Tumors via STING Pathwayactivation. However, no defect of CD8+ T cell priming inMavs/
mice was observed (Figure 1F).
We therefore turned to the other remaining defined pathway
for innate immune sensing that can lead to type I IFN production,
which is cytosolic DNA sensing via the STING pathway. Recent
studies of pathogen sensing have identified a pathway involving
an endoplasmic reticulum resident protein called STING leading
to IRF3 activation and IFN-b transcription (Ishikawa et al., 2009).
STING has been shown to function as an adaptor molecule for
DNA recognition pathways and likely occurs indirectly through
binding of cyclic dinucleotides generated by the enzyme cGAS
(Abe et al., 2013; Burdette et al., 2011;Wu et al., 2013). Strikingly,
in both STING-deficient and IRF3-deficient mice, we observed a
substantially diminished CD8+ T cell response against tumor-
associated antigen in vivo (Figures 1G and 1H), using both
IFN-g ELISPOT and SIY/Kb pentamer analysis (Figures 1I and
1J). These data suggest that STING and IRF3 in host cells are
required for spontaneous CD8+ T cell priming response against
immunogenic tumors.
STING-Deficient Mice and IRF3-Deficient Mice Show
Defective Tumor Control
To assess the role of STING in tumor growth control, we focused
on model systems in which immunogenic tumors were sponta-832 Immunity 41, 830–842, November 20, 2014 ª2014 Elsevier Inc.neously rejected. Methylcholanthrene (MCA)-induced sarcomas
generated in immune-deficient mice are rejected when im-
planted in immune-competent mice due to lack of having been
subjected to immune editing (Matsushita et al., 2012). This was
the case for theMCA-induced sarcoma 1969; however, rejection
of this tumor was eliminated in STING-deficient mice and IRF3-
deficient mice (Figures 2A and 2B). As another approach, in or-
der to have complete rejection of B16.SIY tumor cells, they
were implanted into WT or STING-deficient mice on a 129 ge-
netic background, which is still H-2b but allows tumor rejection
likely due to a contribution of minor histocompatibility antigens.
In contrast to rejection in WT mice, tumors grew progressively
in STING-deficient 129 mice (Figure 2C). We also measured tu-
mor growth of B16.SIY tumors in syngeneic C57BL/6 mice,
and while these tumors are not rejected in WT mice, they none-
theless grew faster in STING-deficient and IRF3-deficient hosts,
indicating a degree of natural immune control that was similarly
STING-dependent (Figures 2D and 2E). In contrast, there was
no difference of B16.SIY tumor growth in betweenWT and Trif/
mice (Figure 2F).
To determine whether the failed tumor rejection in STING-defi-
cient mice was relatively unique to the tumor context versus a
general property of tissue rejection, we investigated skin graft
rejection across minor histocompatibility antigen differences
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STING-deficient male skin into STING-deficient female recipi-
ents was identical compared to WT donor-recipient pairs (Fig-
ure S2). Thus, not all tissue-based T cell rejection processes
are STING-dependent; rather, the tumor context has special
properties that render host T cell priming particularly dependent
on the STING pathway.
Tumor-Derived DNA Induces IFN-b Production by a
cGAS-, STING-, and IRF-3-Dependent Pathway
We turned to an in vitro system to screen fractions of B16 tumor
cell extracts and tumor cells killed using a variety of approaches,
to determine which preparation might be capable of inducing
IFN-b from DCs. Tumor cells killed in multiple ways, including
by mechanical disruption, or supernatants from spent B16 cul-
tures failed to induce IFN-b production by bone-marrow-derived
DCs (Figure 3A). Based on recent reports characterizing a cyto-
solic DNA sensing pathway that can detect intracellular viruses,
bacteria, and Plasmodium falciparum and drive type I IFN pro-
duction (Henry et al., 2007; Sharma et al., 2011; Takaoka et al.,
2007; Unterholzner et al., 2010), we examined whether tumor-
derived DNAmight act similarly. Indeed, B16 melanoma-derived
total DNA combinedwith Lipofectamine provoked IFN-b produc-
tion by DCs (Figure 3A). The inclusion of Lipofectamine was
necessary, suggesting that the DNA needed to gain entry to
the cytosol, as has been reported previously (Stetson andMedz-
hitov, 2006). Treatment of the tumor-derived DNA preparation
with DNase I abolished this stimulatory effect, supporting DNA
as the active component (data not shown). Tumor-derived
RNAwasminimally stimulatory (data not shown). In immortalized
macrophages cells, tumor-derived DNA in combination with Lip-
ofectamine also induced production of IFN-b (Figure S3A). In
addition to tumor-derived DNA, normal cell-derived DNA iso-
lated from splenocytes also induced production of IFN-b by
mouse BMDCs when combined with Lipofectamine in vitro (Fig-
ure S5B), suggesting that there is unlikely to be a unique property
of DNA derived from transformed cells that make it more stimu-
latory. Rather, there must be some characteristic of the tumor
cell context that favors DNA transfer to host APCs as tumors
become established in vivo.
To assess activation of the STING pathway, we performed
immunoblot analysis to assess phosphorylation of TBK1 and
IRF3 after tumor-derived DNA stimulation of bone-marrow-
derived DCs. We indeed observed increased phosphorylation
of TBK1 and IRF3 in DCs from WT mice that was not seen in
DCs from STING-deficient mice. The amount of each protein
was normalized with GAPDH loading control and the ratio of
phosphorylated to total proteins was quantified (pTBK1/TBK1:
WT [2.076] versus STING-deficient [0.705], pIRF3/IRF3: WT
[0.308] versus STING-deficient [0.009]; p < 0.051, p < 0.0001)
(Figure 3B). This amount of phosphorylation of TBK1 and IRF3
was comparable to what we observed with LPS stimulation,
although the latter was preserved in STING-deficient DCs (Fig-
ure S3B). It has been reported that activated STING accumulates
as aggregates in a perinuclear region (Ishikawa et al., 2009).
Induced aggregation of STING was also observed in murine
macrophage cells in response to tumor DNA (Figure 3C).
Recent data have indicated that the ultimate direct ligand
of STING is cyclic dinucleotides, generated in response to cyto-Isolic DNA binding the enzyme cGAS (Sun et al., 2013; Wu et al.,
2013). In the present model, siRNA knockdown of cGAS in mac-
rophages also significantly reduced production of IFN-b in
response to tumor DNA stimulation (Figures S3C and S3D).
IFN-b production was severely blunted with STING-deficient or
IRF3-deficient DCs (Figures 3D and 3E), confirming a require-
ment for this defined pathway for DC activation. As a confirma-
tory approach, we utilized a reporter cell line expressing the
secreted embryonic alkaline phosphatase (SEAP) enzyme driven
by the IFN-b-inducible IFN-induced 54 kDa protein (ISG54) pro-
moter. In this system, specific siRNAs for STING or IRF3 resulted
in substantial inhibition of IFN-b-inducible ISG54 promoter activ-
ity after stimulation with tumor-derived DNA (Figures 3F and 3G).
STING- or IRF3- and IRF7-deficient macrophages also did not
produce IFN-b after tumor-derived DNA stimulation (Figure S3E).
Reintroduction of STING into STING-deficient macrophages
restored production of IFN-b after tumor-DNA stimulation (Fig-
ure S3F). These data indicate that tumor-derived DNA can
induce production of IFN-b when introduced into APCs in vitro,
via a mechanism dependent upon cGAS, STING, and IRF3.
Tumor-Derived DNA Is Transferred to Host APCs In Vivo
Because killed tumor cells in vitro could not recapitulate the
IFN-b production triggered upon tumor implantation in vivo, we
pursued a direct in vivo approach to determine whether tumor-
derived DNA was indeed transferred to host APCs within the
tumor microenvironment and whether this resulted in STING
pathway activation. B16 tumor cells were stained in vitro with
DNA-intercalating dye DRAQ5 prior to implantation in vivo. In or-
der to avoid dilution of the dye as a consequence of cell prolifer-
ation, we performed most of these experiments analyzing host
inflammatory cells 1 day after tumor injection. The early tumor
bump was harvested, disrupted into a single cell suspension,
and analyzed by cytometry. In order to ensure that the analysis
focused exclusively on host myeloid cells and not fusion hetero-
karyons or cell aggregates, single cell analysis using the Amnis
ImageStream instrument was employed. Host DCs were identi-
fied based on staining for CD11c and CD45. Indeed, approxi-
mately 60% of CD45+CD11c+ cells showed positive staining
with tumor-cell-derived DRAQ5, in a diffuse staining pattern (Fig-
ure 4A), whereas controls were negative. Using an in vitro trans-
well system, we found that DRAQ5 transfer was not detected in
nonlabeled cells separated by a membrane, arguing that detec-
tion in DCs was not a consequence of leaking of the DRAQ5 dye
from the tumor cells (data not shown).
As a second approach, B16 tumor cells were labeled with the
nucleotide analog EdU prior to injection into mice. EdU would be
covalently incorporated into DNA and would eliminate concern
for potential dissociation of the DRAQ5 dye and independent up-
take. Similar to DRAQ5, we observed EdU staining on a large
population of tumor-infiltrating CD45+CD11c+ cells (Figure 4B).
We also observed tumor-derived EdU-labeled DNA transfer to
host APCs using the 1969 tumor cell system, arguing that this
phenomenon is not unique to B16 melanoma (Figure S4A).
Compared to DRAQ5 staining, the percentage of EdU-positive
cells in host APCs was consistently lower than that of DRAQ5-
positive cells. This difference could be because only a subset
of the tumor DNA incorporates EdU with this strategy, or
because the EdU labeling is more specific for DNA.mmunity 41, 830–842, November 20, 2014 ª2014 Elsevier Inc. 833
Figure 3. Tumor-Derived DNA Activates STING Pathway and Induces IFN-b via cGAS-, STING-, and IRF3-Dependent Mechanism
(A) Cultured B16 melanoma tumor cells were manipulated or used as a source of material as indicated, and incubated with BM-DCs for 18 hr. The amount of
secreted IFN-b was measured by ELISA.
(B) BM-DC cells from WT or Tmem173/ mice were stimulated with 1 mg/ml of tumor-derived DNA for the indicated time points. The amount of pTBK1, total
TBK1, pIRF3, and total IRF3 was measured by immunoblot.
(C) Asc/macrophages that overexpress STING-HA tag were stimulated with tumor-derived DNA for 1 hr and stained for CD11b, HA-tag, and DAPI. Single cell
images were acquired using the ImageStream instrument and analyzed with IDEAS software.
(D and E) BM-DCs were generated fromWT, Tmem173/, or Irf3/mice and stimulated with tumor DNA in the presence of Lipofectamine. The amount of IFN-b
was measured by ELISA.
(F andG) IFN-b reporter cells were transfectedwith siRNAs specific for STING or IRF3 followed by stimulation with tumor DNA. Reporter activity wasmeasured as
described in Experimental Procedures. **p < 0.01, ***p < 0.001 (Student’s t test). Data represent mean ± SEM and representative of three independent ex-
periments. See also Figure S3.
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Figure 4. Tumor-Infiltrating Host APCs Up-
take Tumor-Derived DNA In Vivo
(A) B16.SIY tumor cells were stained with DRAQ5,
extensively washed, and then inoculated into mice
subcutaneously. The next day, isolated single-cell
suspensions were stained and single cell images
were acquired using ImageStream. Acquired im-
ages were analyzed with IDEAS software.
(B) B16.SIY tumor cells were labeled with EdU,
extensively washed, and then inoculated intomice.
The next day, tumor bumps were harvested and
EdU staining was analyzed by ImageStream.
Nonlabeled tumor cells were used as a negative
control.
(C) B16melanoma cells were stained with EdU and
injected into mice subcutaneously. At day 5, when
tumors were becoming palpable, tumors were
isolated including any infiltrating host cells and
stained to exclude dead cells, along with anti-
CD11c, anti-CD45, and for EdU. Stained cells were
acquired by ImageStream or flow cytometry and
analyzed by IDEAS or FlowJo software.
(D) At day 3 after injection of EdU-labeled B16
melanoma cells, tumor bumps were isolated and
stained with anti-CD45, anti-Lamin A, and for EdU.
Images of stained cells were acquired by Amnis
ImageStream, and colocalization of EdU and
Lamin A signals was analyzed using IDEAS soft-
ware. ***p < 0.001 (Student’s t test). Data indicate
mean ± SEMand representative of at least three (A,
B, and C) or two (D) independent experiments. See
also Figure S4.
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Innate Immune Sensing of Tumors via STING PathwayWewere concerned that the evidence for DNA transfer to host
APCs might be restricted to the first day of tumor cell implanta-
tion, when solid tumors have not yet been established. We there-
fore examined whether tumor-derived EdU could be identified
within APCs at later time points, when the tumor was palpable.Immunity 41, 830–842, NIndeed, EdU persisted in tumor-infiltrating
CD11c+ cells at day 5, after tumors were
clearly palpable (Figure 4C). We also
examined the intracellular localization of
the tumor-derived EdU label by costain-
ing tumor-infiltrating CD45+ cells for the
nuclear marker Lamin A or the lysosomal
marker LAMP-1. Themajority of the signal
did not colocalize with either marker (Fig-
ures 4D and S4B). These latter data also
suggest that the DNA label being seen in
host APCs is not simply present in a
phagocytic compartment, but rather ap-
pears to be localized in the cytosol, which
would provide access to the STING
pathway for engagement.
Tumor-Infiltrating Hosts APCs
Produce IFN-b via a STING-
Dependent Mechanism In Vivo
We investigated whether host APCs
activated the STING pathway and pro-
duced IFN-b within the same time frameas detection of DNA uptake. B16melanoma cells were implanted
subcutaneously, and 1day later the tumor-infiltratingCD45+ cells
were analyzed for phospho-IRF3 induction by ImageStream. As
shown in Figure 5A, despite this being a snapshot in time at an
early time point, approximately 10% of tumor-infiltrating CD45+ovember 20, 2014 ª2014 Elsevier Inc. 835
(legend on next page)
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Innate Immune Sensing of Tumors via STING Pathwaycells showed pIRF3 staining, which appeared to be translocated
to nucleus (Figure 5A). To assess whether the pathway remained
activated at later time points within the stable tumor microenvi-
ronment in a palpable tumor, pIRF3 staining was also examined
within CD11c+ cells in 7 day established B16 melanomas and
wasdetected in similar amounts (Figure 5B). In parallel, activation
of the upstream kinase TBK1 was similarly assessed by phos-
phorylation status and confirmed to be induced in a subset of
CD11c+ cells (Figure S5A).
To assess whether IFN-b was produced by the early tumor-
infiltrating APCs, we isolated tumor-infiltrating CD45+ cells
from WT or STING-deficient mice after injection of B16.SIY
melanoma by flow cytometric sorting, and then performed
quantitative RT-PCR (qRT-PCR). A significant induction of IFN-
b transcripts was observed in CD45+ cells from WT mice but
not from STING-deficient mice (Figure 5C). Flow cytometric
sorting revealed that CD11c+CD11b or CD11c+CD11b+ cells
appeared to be major source of IFN-b production (Figure 5D).
These data are consistent with our previous observations
demonstrating IFN-b production by DCs in the tumor-draining
lymph node with multiple transplantable tumor cell lines (Fuertes
et al., 2011).
To further evaluate whether the tumor context is preferential
for the ability to induce IFN-b from host APCs, we injected the
same number of normal splenocytes subcutaneously, which re-
sulted in minimal induction of IFN-b transcripts compared to B16
tumor cells (Figure 5E). This is despite the fact that purified DNA
from splenocytes and B16 cells induced similar amounts of IFN-
b production from BM-DCs when combined with Lipofectamine
in vitro (Figure S5B). These data suggest that the simple pres-
ence of a cell suspension in the subcutaneous space is not suf-
ficient to activate the STING pathway. We also observed that the
splenocyte injection site evoked markedly diminished DC accu-
mulation compared to tumor cell injection (Figure S5C), suggest-
ing that tumor cells are more capable of initiating innate immune
activation via APCs.
We were also concerned with the possibility that STING
pathway activation and IFN-b production might only occur with
transplantable tumor models. Therefore, a genetic melanoma
model was employed, driven by conditional active B-Raf expres-
sion and PTEN deletion in the melanocyte lineage using tyrosi-
nase-CreER (Dankort et al., 2009). Once tumors were induced
with 4-OH tamoxifen, tumors were harvested and CD45+ host
cells were isolated by flow cytometric sorting. Indeed, IFN-b
transcripts were detected in CD45+ host cells within the tumorFigure 5. Tumor-Infiltrating Host APCs Produce IFN-b via a STING-De
(A) B16.SIY tumor cells were inoculated into mice subcutaneously. The next d
meabilized, and stained with the indicated antibodies. Acquired images with Ima
(B) B16.SIY melanoma cells were injected into mice. After 1 week, tumors were
antibodies. Acquired images were analyzed by Amnis software (IDEAS).
(C and D) B16.SIY tumor cells were inoculated into WT or Tmem173/mice. The
stained with anti-mouse CD45 antibody (C) and CD11b and CD11c (D) antibodies
measured by q-RT-PCR. CD11b+ or CD11c+ cells from lymph nodes or spleen w
(E) Splenocytes were isolated from CD45.1 mice and injected into CD45.2+ C57
sorted by flow cytometry for analysis of IFN-b transcript expression. B16 melano
(F) CD45+ CD19 CD3 live cells were isolated from skin or tumor, LN and sp
BrafV600E Pten/ tumor-bearing mice using cell sorting. Expression of IFN-b trans
each samples). *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s t test). Data indicat
pendent experiments. See also Figures S5 and S6.
Iand in the tumor-draining lymph nodes but not in skin or lymph
node of tumor-free control littermates (Figure 5F). These tumors
also showed presence of a modest T cell infiltrate, consistent
with host immune activation (data not shown). Additional cell
sorting for CD11c+ cells also revealed IFN-b transcripts (Fig-
ure S6A), and pIRF3 induction was detected in approximately
8% of DCs by ImageStream (Figure S6B). Combined with our
observation that the STING pathway is dispensable for skin allo-
graft rejection, this observation reinforces the notion that the
context of a growing tumor in vivo is particularly predisposed
toward induction of STING pathway activation and IFN-b pro-
duction in vivo and separates that property from the technical
aspects of percutaneous injection.
STING-Deficient Hosts Fail to Maintain Specific T Cell
Expansion Consistent with an Effect on Costimulation
To evaluate in more detail the mechanism by which absence of
host STING resulted in impaired antitumor T cell responses
in vivo, we adoptively transferred CFSE-labeled 2C TCR Tg
T cells into WT and STING-deficient mice and measured T cell
proliferation by CFSE dilution after B16.SIY challenge. Interest-
ingly, a similar number of cell divisions were observed in both re-
cipients, but the CFSE-diluted 2C cells failed to accumulate in
STING-deficient mice, in the spleen and lymph nodes (Figures
6A and 6B). This is a pattern that has been seen in other models
of poor T cell costimulation leading to nonproductive T cell acti-
vation (Abe et al., 2013; Hoebe et al., 2003) and suggests that the
STING pathway might be required not only for IFN-b production
but also for expression of other T cell costimulatory factors. To
evaluate a potentially broader DC activation property of DNA,
we generated bone-marrow-derived DCs from WT or STING-
deficient mice, stimulated them with tumor-derived DNA, and
performed gene-expression profiling. Tumor-derived DNA
induced expression of a broad spectrum of genes encodingmul-
tiple critical cofactors for T cell activation, including cytokines
(e.g., IL-12), chemokines (e.g., CXCL9), and costimulatory mole-
cules (e.g., CD86 and CD40; Figure 6C) in WT, but not STING-
deficient, DCs. ELISA confirmed STING-dependent induction
of IL-6, tumor necrosis factor alpha (TNF-a), and IL-12 (Figures
6D–6F) by tumor DNA. Induction of these factors by DNA was
intact in bone-marrow-derived DCs from both Myd88/ and
Trif/ mice, confirming a TLR-independent mechanism of this
DC activation (data not shown). This broader DC activation
pattern might explain ability of this DNA sensing pathway to fully
prime tumor antigen-specific CD8+ T cells in vivo.pendent Fashion In Vivo
ay, tumor bumps were harvested and the suspended cells were fixed, per-
geStream were analyzed using IDEAS software.
harvested and host immune cells were isolated and stained with the indicated
next day, tumor cells, lymph nodes, and spleens were isolated as above and
. Stained cell populations were isolated by cell sorting. Expression of IFN-bwas
ere used as controls.
BL/6 mice. After 1 day, associated infiltrating CD45.2+ cells were stained and
ma cells were used as a control with the same procedure.
leen of either healthy, nontamoxifen treated littermates or tamoxifen-treated
cript was measured by qPCR. *p = 0.05 (one-sidedMann-Whitney U test, n = 3
e mean ± SEM and representative of two (B and G) or three (A and C–F) inde-
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Figure 6. Tmem173–/– Mice Show Defective Accumulation of Antitumor T Cells
(A and B) CFSE-labeled 2C T cell were transferred into WT or Tmem173/mice and B16.SIY melanoma cells were inoculated into recipient mice after 1 day. On
day 6, mice were sacrificed and spleens and tumor-draining lymph nodes were removed. Cells were stained with anti-CD8 and the clonotypic mAb 1B2 and
analyzed by flow cytometry for CFSE dilution. Data were analyzed by FlowJo software and quantitated as shown in the panels on the right.
(C) BM-DCs fromWT or Tmem173/mice were stimulated with tumor DNA for 7 hr and RNA was isolated. Isolated RNA was analyzed by Affymetrix GeneChip
analysis.
(legend continued on next page)
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Innate Immune Sensing of Tumors via STING PathwayIf our model is correct and innate immune sensing via the host
STING pathway is necessary for maximal spontaneous T cell
priming against tumor antigens, and if that spontaneous immune
response is a critical determinant of activity of immunotherapies,
then immunotherapies should lose efficacy in STING-deficient
hosts. To test this notion, we treated tumor-bearing WT or
STING-deficient mice with anti-CTLA-4 and anti-PDL1 mAbs,
which we have shown to have strong synergistic therapeutic
efficacy (Spranger et al., 2014). In fact, most of the therapeutic
effect was lost in STING-deficient mice (Figure 6G). These data
suggest that the host STING pathway can play a critical role in
the therapeutic efficacy of cancer immunotherapies.
DISCUSSION
Our results indicate that the host STING pathway is particularly
critical for innate immune sensing of immunogenic tumors, a
process that results in APC activation, IFN-b production, and
priming of CD8+ T cells against tumor antigens in vivo. Our
data suggest that tumor-derived DNA is the likely ligand for
this pathway, which becomes taken up by host APCs much
like protein antigens, becomes localized to the cytosol, and
is associated with phosphorylation of TBK1 and IRF3 and
STING-dependent production of IFN-b in vivo. The failure of
immunogenic tumors to be rejected in STING-deficient mice
indicates the critical role for this overall process of immune-
mediated tumor control in vivo. With most transplantable
tumors, this initial STING-dependent priming occurs yet the tu-
mor nonetheless eventually grows progressively. Other work
has indicated that immune escape in these cases is mediated
by immune inhibitory mechanisms that function at within the
tumor microenvironment (Gajewski and Schumacher, 2013;
Spranger et al., 2013). Blockade of these immune inhibitory fac-
tors, such as CTLA-4 and PD-L1-PD-1 interactions, is effica-
cious in WT mice, but we found that most of the therapeutic
effect is lost in STING-deficient mice. Thus, innate immune
sensing via the host STING pathway is critical for optimal tumor
control by checkpoint blockade therapies.
An unresolved question in our current work is by what mech-
anism DNA can gain access to the cytosol of DCs under physio-
logic conditions in vivo. Presumably this occurs when a subset
of tumor cells dies, perhaps in areas of hypoxia or nutrient star-
vation that are known to occur in solid tumors in vivo. One candi-
datemechanism of DNA transfer is through binding to the antimi-
crobial peptide LL37 (Lande et al., 2007). Another possibility
is through the CLEC9A receptor that can mediate uptake of ma-
terial from dying cells by DCs, particularly the CD8a+ subset
(Sancho et al., 2009). Chaperoning of tumor-derived DNA by
high-mobility group box 1 (HMGB1) is another potential mecha-
nism (Yanai et al., 2009), which based on our results would likely
be via a TLR-independent fashion. A fourth possibility is through
uptake of autophagosomes, which have been shown to contain(D–F) BM-DCs from WT or Tmem173/ mice were stimulated with tumor DNA a
(G) Mice were injected with 1 3 106 B16-SIY cells on day 0. On day 4, combin
administered intraperitoneally on days 4, 7, and 10, and anti-PD-L1mAb (100 mg/m
growthwasmeasured on the indicated days. Data represent mean ± SEM (n = 10,
was determined using two-way ANOVA test. *p < 0.05, **p < 0.01, ***p < 0.001, ****
(n = 5) and representative of two (A and B) or three (C–F) independent experimen
IDNA (Oka et al., 2012) or through released exosomes. Knock-
down of Beclin1 in tumor cells has been shown to blunt subse-
quent T cell priming in vivo (Li et al., 2008), and purified autopha-
gosomes from tumors have been shown to serve as a potent
vaccine platform in preclinical models (Twitty et al., 2011). The
uncertain cell biology of the process of DNA transfer to APCs
is reminiscent of the still poorly characterized process by which
protein antigens are taken up from extracellular sources and gain
access to the cytosol for proteasomal degradation and presen-
tation by class IMHCmolecules, which also occurs preferentially
by selected APCs in vivo. It is attractive to speculate that there
might be common features between these two processes.
The question arises as to why free DNA is not highly immune
stimulatory in vitro or in vivo. It seems likely that extracellular
DNA will be degraded rapidly by DNase I and DNA taken up by
phagocytosis would be degraded by DNase II. Knockout mice
lacking either of these DNases have been shown to be predis-
posed toward autoimmunity (Kawane et al., 2006; Napirei
et al., 2000), indicating a particular importance for host control
of extracellular DNA content in order to regulate endogenous
immune responses. Consistent with this model, DNase II condi-
tional knockout mice develop an inflammatory syndrome that
leads to death of the animals, which has been reported to be
eliminated upon crossing to a STING-deficient background
(Ahn et al., 2012).
It is worth contrasting the STING-dependent mechanism we
have observed as critical for spontaneous T cell priming against
tumors with mechanistic data regarding immunogenic cell
death induced by certain chemotherapeutic agents (Kroemer
et al., 2013). In those studies, the adaptive immune response
was facilitated upon tumor cell exposure to chemotherapy.
Dying tumor cells were shown to expose calreticulin (CRT)
and release high-mobility group box 1 (HMGB1) and ATP.
CRT interacts with CD91 on dendritic cells, serving as an
‘‘eat-me’’ signal. According to this model, HMGB1 serves as
a ligand for TLR4 on DCs and activates them via MyD88. ATP
released from disrupted tumor cells also has been reported to
activate the inflammasome pathway to produce IL-1b via
P2X7 receptors (Apetoh et al., 2007; Ghiringhelli et al., 2009;
Obeid et al., 2007). In our own studies, we have found that mul-
tiple transplantable tumor models induce spontaneous IFN-b
production from host cells (Fuertes et al., 2013) and the host
STING pathway is required. However, spontaneous T cell prim-
ing appears to be independent from MyD88 and P2X7R. Thus,
the mechanisms of innate immune sensing might be partially
distinct based on whether spontaneous or chemotherapy-
induced immune responses are being evaluated. Identifying
strategies to optimize the triggering of multiple innate immune
sensing pathways concurrently might be important to consider
from the therapeutic perspective.
A subset of human patients with melanoma shows sponta-
neous generation of an antitumor T cell response, whereasnd the indicated cytokines were measured by ELISA.
atorial antibody therapy was initiated. Anti-CTLA-4 mAb (100 mg/mouse) was
ouse) was given every other day starting on day 4 and ending on day 16. Tumor
each group) of combined two independent experiments. Statistical significance
p < 0.0001 (Student’s t test or two-way ANOVA test). Data indicatemean ± SEM
ts.
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Innate Immune Sensing of Tumors via STING Pathwayanother major subset shows no such spontaneous immunity
(Gajewski, 2006). A subset of patients with ovarian cancer
(Hwang et al., 2012), breast cancer (Mahmoud et al., 2011),
and colorectal cancer (Galon et al., 2006) displays spontaneous
tumor infiltration with T cells. In the colorectal cancer example,
the presence of activated CD8+ T cells in the tumor site has
been reported to be a more powerful prognostic factor than tu-
mor stage (Page`s et al., 2009), arguing for the critical functional
importance of this natural antitumor immune response in pa-
tients. It seems plausible that an underlying mechanism explain-
ing the presence or absence of this natural immune response
might be whether appropriate innate immune sensing of the
presence of tumor cells is occurring. Knowledge of the impor-
tance of the STING pathway will provide tools for probing human
cancers for candidate defects correlating with the lack of spon-
taneous T cell infiltration. Facilitating this process when it does
not occur de novo through the use of STING agonists could pro-
vide a therapeutic strategy to initiate endogenous T cell priming.
EXPERIMENTAL PROCEDURES
Mice and Cells
C57BL/6 mice and 129 mice were obtained from Jackson and Taconic.
Myd88/, Trif/, P2x7r/, andMavs/mice were purchased from Jackson
ImmunoResearch Laboratories. Tlr4/mice were provided by Dr. Cathryn
Nagler and Dr. Haochu Huang (University of Chicago), and Tlr9/ mice
were purchased from Oriental Bioservice. Tmem173/ (STING-deficient)
mice were generated by Dr. G. Barber (University of Miami). Irf3/ (IRF3-defi-
cient) mice were obtained from RIKEN Bio Resource Center. The C57BL6-
derived melanoma cell line B16.F10.SIY (henceforth referred to as B16.SIY)
was generated as described (Blank et al., 2005). 1969 sarcomas tumor cells
were gifted by Dr. Robert Schreiber (Washington University). All cells were
cultured in complete DMEM media supplemented 10% heat-inactivated
FCS. For measurement of type I IFN reporter activity, B16-Blue IFN reporter
cells were purchased from InvivoGen and maintained according to the
manufacturer’s instructions. Animals were used according to protocols
approved by the IACUC of University of Chicago according to NIH guidelines
for animal use.
2C CD8+ T Cell Purification, CFSE Staining, and Adoptive Transfer
2C TCR Tg CD8+ T cells were isolated from spleens and lymph nodes of 2C/
RAG2/ mice by using magnetic beads. T cells were loaded with 2.5 mM
CFSE and transferred intoWT or designated gene-targeted mice (43 106 cells
per mouse). After 1 day, recipient mice received 106 B16.SIY cells, and 5 days
later splenocytes from recipient mice were analyzed after staining with anti-
mouse CD8a-APC and biotin-labeled anti-2C-TCR (1B2) with SA-PE by flow
cytometry to assess CFSE dilution.
IFN-g ELISPOT and Pentamer Staining
Splenocytes were plated at 106 cells per well and stimulated overnight with SIY
peptide. Spots were developed using the BDmouse IFN-g kit, and the number
of spots was measured using an Immunospot Series 3 Analyzer and analyzed
using ImmunoSpot software (Cellular Technology). For pentamer staining,
cells were labeled with PE-MHC class I pentamer (Proimmune) consisting of
murine H-2Kb complexed to SIYRYYGL (SIY) peptide, anti-CD8-APC (53-
6.7), anti-CD19-PerCP-Cy5.5 (6D5), and anti-CD4-PerCP-Cy5.5 (RM4-5).
Stained cells were analyzed using FACSCanto or LSR II cytometers with
FACSDiva software (BD). Data analysis was conducted with FlowJo software
(Tree Star).
Preparation of B16 Melanoma Extracts for Potential IFN-b Induction
In Vitro
For generation of B16 melanoma-derived extracts, cultured tumor cells were
treated with staurosporin (0.5 mM) for 4 hr, irradiated (15,000 rad), incubated
for 1 hr at 55C for heat killing, mechanically killed using 10 passages through840 Immunity 41, 830–842, November 20, 2014 ª2014 Elsevier Inc.a syringe and needle, or treated 3 times by freezing and thawing cycles using
liquid nitrogen and water bath at 37C. For tumor-derived genomic DNA isola-
tion, B16 tumor cells were washed with PBS and DNA was isolated using
Blood & Cell Culture DNA Midi Kit (QIAGEN). The concentration and purity of
DNA was determined by NanoDrop 1000 (Thermo Scientific). Each cell extract
was added into BM-DCs and incubated for 18 hr at 37C and amount of IFN-b
was measured by ELISA.
In Vitro IFN-bMeasurement
The IFN-b reporter cell line was cultured in 96-well plates and stimulated with
tumor-derived DNA (20 ng/well) with Lipofectamine 2000 (0.75 ml/well) (Invitro-
gen) for 18 hr. Bone-marrow-derived dendritic cells (BM-DCs) were generated
by culturing bone-marrow cells in the presence of rmGM-CSF (20 ng/ml; Bio-
Legend) for 9 days followed by stimulation with tumor-derived DNA (20 ng/
well) for 7 hr. After incubation, supernatant was collected and IFN-b was
measured by ELISA (PBL IFN source) or adding substrate (QUANTI-Blue; In-
vivoGen) for the reporter cell line.
Statistical Analysis
The Student’s t test, two-way ANOVA and one-sided Mann-Whitney U test
were used for statistical analysis. p values < 0.05 were considered statistically
significant.
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